Compare Lupin with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs BIOCON - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN BIOCON LUPIN/
BIOCON
 
P/E (TTM) x -299.9 31.6 - View Chart
P/BV x 3.9 3.8 103.7% View Chart
Dividend Yield % 0.6 0.3 212.2%  

Financials

 LUPIN   BIOCON
EQUITY SHARE DATA
    LUPIN
Mar-20
BIOCON
Mar-19
LUPIN/
BIOCON
5-Yr Chart
Click to enlarge
High Rs882707 124.7%   
Low Rs505554 91.2%   
Sales per share (Unadj.) Rs339.491.9 369.3%  
Earnings per share (Unadj.) Rs-5.916.7 -35.6%  
Cash flow per share (Unadj.) Rs15.524.2 64.0%  
Dividends per share (Unadj.) Rs6.001.00 600.0%  
Dividend yield (eoy) %0.90.2 545.5%  
Book value per share (Unadj.) Rs276.7101.6 272.3%  
Shares outstanding (eoy) m453.00600.00 75.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.06.9 29.8%   
Avg P/E ratio x-116.637.7 -309.1%  
P/CF ratio (eoy) x44.826.1 171.9%  
Price / Book Value ratio x2.56.2 40.4%  
Dividend payout %-100.96.0 -1,685.9%   
Avg Mkt Cap Rs m314,201378,330 83.0%   
No. of employees `00018.36.1 298.5%   
Total wages/salary Rs m29,86811,653 256.3%   
Avg. sales/employee Rs Th8,400.68,994.3 93.4%   
Avg. wages/employee Rs Th1,632.01,900.7 85.9%   
Avg. net profit/employee Rs Th-147.21,635.3 -9.0%   
INCOME DATA
Net Sales Rs m153,74855,144 278.8%  
Other income Rs m4,8381,444 335.0%   
Total revenues Rs m158,58556,588 280.2%   
Gross profit Rs m24,84915,883 156.5%  
Depreciation Rs m9,7024,478 216.7%   
Interest Rs m3,630709 512.0%   
Profit before tax Rs m16,35512,140 134.7%   
Minority Interest Rs m49 43.3%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5712,123 545.0%   
Profit after tax Rs m-2,69410,026 -26.9%  
Gross profit margin %16.228.8 56.1%  
Effective tax rate %70.817.5 404.6%   
Net profit margin %-1.818.2 -9.6%  
BALANCE SHEET DATA
Current assets Rs m154,13248,228 319.6%   
Current liabilities Rs m92,25230,376 303.7%   
Net working cap to sales %40.232.4 124.3%  
Current ratio x1.71.6 105.2%  
Inventory Days Days8268 120.2%  
Debtors Days Days12986 151.2%  
Net fixed assets Rs m89,08264,130 138.9%   
Share capital Rs m9063,000 30.2%   
"Free" reserves Rs m124,46157,980 214.7%   
Net worth Rs m125,36760,980 205.6%   
Long term debt Rs m17,93315,766 113.7%   
Total assets Rs m249,839121,924 204.9%  
Interest coverage x5.518.1 30.4%   
Debt to equity ratio x0.10.3 55.3%  
Sales to assets ratio x0.60.5 136.1%   
Return on assets %0.48.8 4.3%  
Return on equity %-2.116.4 -13.1%  
Return on capital %8.716.8 52.1%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m51,45015,506 331.8%   
Fx outflow Rs m19,47010,399 187.2%   
Net fx Rs m31,9805,107 626.2%   
CASH FLOW
From Operations Rs m14,68811,546 127.2%  
From Investments Rs m11,070-7,138 -155.1%  
From Financial Activity Rs m-8,906-2,417 368.5%  
Net Cashflow Rs m16,8532,103 801.4%  

Share Holding

Indian Promoters % 46.6 40.4 115.3%  
Foreign collaborators % 0.2 20.6 1.0%  
Indian inst/Mut Fund % 11.3 8.4 134.5%  
FIIs % 31.9 10.7 298.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 19.9 50.8%  
Shareholders   98,259 109,995 89.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SUVEN LIFE SCIENCES  NEULAND LABS  PIRAMAL ENTERPRISES  TTK HEALTHCARE  SUN PHARMA  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jan 25, 2021 (Close)

TRACK LUPIN

LUPIN - PIRAMAL ENTERPRISES COMPARISON

COMPARE LUPIN WITH

MARKET STATS